Sugi Predict

Sugi Predict / Compounds / SCHEMBL536846

SCHEMBL536846

SCHEMBL536846

CCCc1cc(=O)oc2cc(O)ccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B3 P37058 13/20 1.00
▸ ALDH1A1 P00352 5/20 0.83
▸ GAA P10253 3/20 0.83
▸ ERAP1 Q9NZ08 1/20 0.83
▸ AKR1B1 P15121 2/20 0.64
▸ LCK P06239 1/20 0.64
▸ FYN P06241 1/20 0.64
▸ GRB2 P62993 1/20 0.64
▸ KDM4E B2RXH2 5/20 0.62
▸ GLA P06280 2/20 0.62
▸ HPGD P15428 2/20 0.59
▸ CA12 O43570 1/20 0.59
▸ LMNA P02545 1/20 0.59
▸ CYP1A2 P05177 1/20 0.59
▸ CYP2C9 P11712 1/20 0.59
▸ UGT1A1 P22309 1/20 0.59
▸ MAOB P27338 1/20 0.59
▸ CASP1 P29466 1/20 0.59
▸ KDR P35968 1/20 0.59
▸ CASP7 P55210 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3762732 0.89 HSD17B3 (1.00) HSD17B3ALDH1A1GAAERAP1AKR1B1
SCHEMBL592465 0.88 ALDH1A1 (0.89) HSD17B3ALDH1A1GAAERAP1AKR1B1
SCHEMBL29558522 0.88 ALDH1A1 (0.89) HSD17B3ALDH1A1GAAERAP1AKR1B1
SCHEMBL18721220 0.88 HSD17B3 (0.78) HSD17B3ALDH1A1GAAERAP1AKR1B1
SCHEMBL4215955 0.86 HSD17B3 (0.75) HSD17B3ALDH1A1GAAERAP1AKR1B1
SCHEMBL12433414 0.84 HSD17B3 (0.73) HSD17B3ALDH1A1GAAERAP1AKR1B1
SCHEMBL27469537 0.84 HSD17B3 (0.73) HSD17B3ALDH1A1GAAERAP1AKR1B1
SCHEMBL15082521 0.84 HSD17B3 (0.72) HSD17B3ALDH1A1GAAERAP1AKR1B1
SCHEMBL15082514 0.84 HSD17B3 (0.72) HSD17B3ALDH1A1GAAERAP1AKR1B1
Umbelliferone SCHEMBL3762137 0.83 HSD17B3 (0.70) HSD17B3ALDH1A1GAAERAP1AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025042896-A1 DNA TOPOISOMERASE IIβ INHIBITORS MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2025-02-27 — — WO disclosed
US-10323013-B2 Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2019-06-18 — — US disclosed
EP-2700717-B1 Method for the diagnosis of lysosomal storage diseases PRZYBYLSKI MICHAEL (DE) 2016-06-01 — — EP disclosed
US-9075014-B2 pH-responsive fluorescent false neurotransmitters and their use THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2015-07-07 — — US disclosed
US-9075014-B2 pH-responsive fluorescent false neurotransmitters and their use THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2015-07-07 — — US disclosed
EP-2700717-A1 Method for the diagnosis of lysosomal storage diseases Universität Konstanz (DE) 2014-02-26 — — EP disclosed
US-20130171664-A1 PH-RESPONSIVE FLUORESCENT FALSE NEUROTRANSMITTERS AND THEIR USE THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2013-07-04 — — US disclosed
US-8476336-B2 Ophthalmologic composition and ophthalmologic lens ACRI.TEC GMBH (DE) 2013-07-02 — — US disclosed
US-8476336-B2 Ophthalmologic composition and ophthalmologic lens ACRI.TEC GMBH (DE) 2013-07-02 — — US disclosed
US-8476336-B2 Ophthalmologic composition and ophthalmologic lens ACRI.TEC GMBH (DE) 2013-07-02 — — US disclosed
US-20050154050-A1 Compound REED MICHAEL J (GB) 2005-07-14 — — US disclosed
EP-0904079-B1 ANTIDIABETIC AGENTS MERCK & CO INC (US) 2004-03-24 — — EP disclosed
EP-0904079-A4 — — 1999-05-06 — — EP disclosed
EP-0904079-A1 ANTIDIABETIC AGENTS Merck & Co., Inc. (US) 1999-03-31 — — EP disclosed
US-5859051-A ACETYLPHENOL DERIVATIVES MERCK & CO., INC. (US) 1999-01-12 — — US disclosed
WO-1997027857-A1 ANTIDIABETIC AGENTS MERCK & CO., INC. (US) 1997-08-07 — — WO disclosed
EP-0411912-B1 Coumarin derivatives, their preparation and their use in the treatment of cerebrovascular disorders SANKYO CO (JP) 1995-04-19 — — EP disclosed
EP-0411912-A2 Coumarin derivatives, their preparation and their use in the treatment of cerebrovascular disorders Sankyo Company Limited (JP) 1991-02-06 — — EP disclosed
US-4701456-A SCHIZOPHRENIA WARNER-LAMBERT COMPANY (US) 1987-10-20 — — US disclosed
EP-0175541-A1 Aminoalkoxybenzopyranones and processes for the production thereof WARNER-LAMBERT COMPANY (US) 1986-03-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10323013-B2 Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof XBP1, ERN1, SREBF1 HSD17B3 2620/4885ALDH1A1 2127/4885GAA 3369/4885
US-20050154050-A1 Compound HSD17B11, NR5A1, CYP17A1 HSD17B3 10/4885ALDH1A1 611/4885GAA 1571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.